Quinazoline compounds
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61388963%3A_____%2F19%3A00534505" target="_blank" >RIV/61388963:_____/19:00534505 - isvavai.cz</a>
Result on the web
<a href="https://worldwide.espacenet.com/publicationDetails/originalDocument?CC=US&NR=10206926B2&KC=B2&FT=D&ND=4&date=20190219&DB=&locale=en_EP" target="_blank" >https://worldwide.espacenet.com/publicationDetails/originalDocument?CC=US&NR=10206926B2&KC=B2&FT=D&ND=4&date=20190219&DB=&locale=en_EP</a>
DOI - Digital Object Identifier
—
Alternative languages
Result language
angličtina
Original language name
Quinazoline compounds
Original language description
Described herein are compounds of Formula (I) and tautomers and pharmaceutical salts thereof, compositions and formulations containing such compounds, and methods of using and making such compounds.
Czech name
—
Czech description
—
Classification
Type
P - Patent
CEP classification
—
OECD FORD branch
10401 - Organic chemistry
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2019
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Patent/design ID
US10206926
Publisher
US001 -
Publisher name
United States Patent and Trademark Office (USPTO)
Place of publication
Alexandria
Publication country
US - UNITED STATES
Date of acceptance
Feb 19, 2019
Owner name
Gilead Sciences, Inc. - Ústav organické chemie a biochemie AV ČR, v. v. i
Method of use
B - Výsledek je využíván orgány státní nebo veřejné správy
Usage type
A - K využití výsledku jiným subjektem je vždy nutné nabytí licence